IL112834A - Pharmaceutical compositions for controlled release of soluble receptors - Google Patents

Pharmaceutical compositions for controlled release of soluble receptors

Info

Publication number
IL112834A
IL112834A IL11283495A IL11283495A IL112834A IL 112834 A IL112834 A IL 112834A IL 11283495 A IL11283495 A IL 11283495A IL 11283495 A IL11283495 A IL 11283495A IL 112834 A IL112834 A IL 112834A
Authority
IL
Israel
Prior art keywords
pct
controlled release
pharmaceutical compositions
soluble receptors
ligand
Prior art date
Application number
IL11283495A
Other languages
English (en)
Other versions
IL112834A0 (en
Inventor
David Wallach
Joseph Kost
Rom Eliaz
Original Assignee
Yeda Res & Dev
Univ Ben Gurion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev, Univ Ben Gurion filed Critical Yeda Res & Dev
Priority to IL11283495A priority Critical patent/IL112834A/xx
Publication of IL112834A0 publication Critical patent/IL112834A0/xx
Priority to UA97094438A priority patent/UA44761C2/uk
Priority to AU53039/96A priority patent/AU692384B2/en
Priority to JP52645796A priority patent/JP4447052B2/ja
Priority to ES96909604T priority patent/ES2318849T3/es
Priority to EP96909604A priority patent/EP0812208B1/en
Priority to PT96909604T priority patent/PT812208E/pt
Priority to DK96909604T priority patent/DK0812208T3/da
Priority to BR9607289A priority patent/BR9607289A/pt
Priority to CNB961934379A priority patent/CN1133464C/zh
Priority to MX9706626A priority patent/MX9706626A/es
Priority to KR1019970706046A priority patent/KR100417650B1/ko
Priority to PCT/US1996/003121 priority patent/WO1996026738A1/en
Priority to AT96909604T priority patent/ATE415941T1/de
Priority to EA199700206A priority patent/EA199700206A1/ru
Priority to DE69637768T priority patent/DE69637768D1/de
Priority to US08/894,913 priority patent/US6083534A/en
Priority to CA2213560A priority patent/CA2213560C/en
Priority to NO19973812A priority patent/NO323003B1/no
Publication of IL112834A publication Critical patent/IL112834A/xx
Priority to NO20056197A priority patent/NO328034B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL11283495A 1995-03-01 1995-03-01 Pharmaceutical compositions for controlled release of soluble receptors IL112834A (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
IL11283495A IL112834A (en) 1995-03-01 1995-03-01 Pharmaceutical compositions for controlled release of soluble receptors
UA97094438A UA44761C2 (uk) 1995-03-01 1996-01-03 ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ІЗ КОНТРОЛЬОВАНИМ ВИДІЛЕННЯМ РОЗЧИННОГО TNF-<font face="Symbol">a</font> РЕЦЕПТОРА ТА СПОСОБИ ЛІКУВАННЯ
CA2213560A CA2213560C (en) 1995-03-01 1996-03-01 Pharmaceutical compositions for controlled release of soluble receptors
BR9607289A BR9607289A (pt) 1995-03-01 1996-03-01 Composiçoes farmacêuticas para administraçao controlada de receptores solúveis
KR1019970706046A KR100417650B1 (ko) 1995-03-01 1996-03-01 가용성수용기의조절방출용약제조성물
ES96909604T ES2318849T3 (es) 1995-03-01 1996-03-01 Composiciones farmaceuticas para el suministro controlado de receptores solubles.
EP96909604A EP0812208B1 (en) 1995-03-01 1996-03-01 Pharmaceutical compositions for controlled release of soluble receptors
PT96909604T PT812208E (pt) 1995-03-01 1996-03-01 Composições farmacêuticas para libertação controlada de receptores solúveis
DK96909604T DK0812208T3 (da) 1995-03-01 1996-03-01 Farmaceutiske sammensætninger til kontrolleret frigivelse af oplöselige receptorer
AU53039/96A AU692384B2 (en) 1995-03-01 1996-03-01 Pharmaceutical compositions for controlled release of soluble receptors
CNB961934379A CN1133464C (zh) 1995-03-01 1996-03-01 控制释放可溶性受体的药物组合物
MX9706626A MX9706626A (es) 1995-03-01 1996-03-01 Composiciones farmaceuticas para la liberacion controlada de receptores solubles.
JP52645796A JP4447052B2 (ja) 1995-03-01 1996-03-01 可溶性レセプターの制御された放出のための医薬組成物
PCT/US1996/003121 WO1996026738A1 (en) 1995-03-01 1996-03-01 Pharmaceutical compositions for controlled release of soluble receptors
AT96909604T ATE415941T1 (de) 1995-03-01 1996-03-01 Arzneitmittel zur kontrollierten freisetzung löslicher rezeptoren
EA199700206A EA199700206A1 (ru) 1995-03-01 1996-03-01 Фармацевтические композиции для контролируемого высвобождения растворимых рецепторов
DE69637768T DE69637768D1 (de) 1995-03-01 1996-03-01 Arzneitmittel zur kontrollierten freisetzung löslicher rezeptoren
US08/894,913 US6083534A (en) 1995-03-01 1996-03-01 Pharmaceutical compositions for controlled release of soluble receptors
NO19973812A NO323003B1 (no) 1995-03-01 1997-08-19 Farmasoytiske sammensetninger til svekkelse av de skadelige effekter av Tumor Nekrose Faktor-alfa (TNF-alfa) samt anvendelse derav.
NO20056197A NO328034B1 (no) 1995-03-01 2005-12-27 Farmasoytiske sammensetninger for kontrollert frigjoring av TNF-alfa

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL11283495A IL112834A (en) 1995-03-01 1995-03-01 Pharmaceutical compositions for controlled release of soluble receptors

Publications (2)

Publication Number Publication Date
IL112834A0 IL112834A0 (en) 1995-06-29
IL112834A true IL112834A (en) 2000-12-06

Family

ID=11067150

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11283495A IL112834A (en) 1995-03-01 1995-03-01 Pharmaceutical compositions for controlled release of soluble receptors

Country Status (19)

Country Link
US (1) US6083534A (no)
EP (1) EP0812208B1 (no)
JP (1) JP4447052B2 (no)
KR (1) KR100417650B1 (no)
CN (1) CN1133464C (no)
AT (1) ATE415941T1 (no)
AU (1) AU692384B2 (no)
BR (1) BR9607289A (no)
CA (1) CA2213560C (no)
DE (1) DE69637768D1 (no)
DK (1) DK0812208T3 (no)
EA (1) EA199700206A1 (no)
ES (1) ES2318849T3 (no)
IL (1) IL112834A (no)
MX (1) MX9706626A (no)
NO (2) NO323003B1 (no)
PT (1) PT812208E (no)
UA (1) UA44761C2 (no)
WO (1) WO1996026738A1 (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10510540A (ja) 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US7067144B2 (en) * 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
EP1206275B1 (en) * 1998-11-05 2007-09-05 Omeros Corporation Irrigation solution and method for inhibition of pain and inflammation
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7807211B2 (en) * 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
EP1216037A2 (en) * 1999-09-21 2002-06-26 Emory University Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
US8632845B2 (en) * 2000-12-28 2014-01-21 Abbott Cardiovascular Systems Inc. Method of drying bioabsorbable coating over stents
AU2003209755B2 (en) * 2002-02-06 2007-11-22 Ares Trading S.A. Tumor necrosis factor combined with interferon in demyelinating diseases
PT2561860T (pt) * 2002-05-31 2018-05-08 Titan Pharmaceuticals Inc Dispositivo polimérico implantável para a libertação prolongada de buprenorfina
ES2601143T3 (es) * 2002-07-19 2017-02-14 Omeros Corporation Copolímeros tribloque biodegradables, métodos de síntesis de los mismos, e hidrogeles y biomateriales preparados a partir de los mismos
CN102772357B (zh) 2003-03-31 2014-12-31 泰坦医药品公司 用于持续释放多巴胺受体激动剂的可植入聚合物装置
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US20060046960A1 (en) * 2004-09-02 2006-03-02 Mckay William F Controlled and directed local delivery of anti-inflammatory compositions
US20060046961A1 (en) * 2004-09-02 2006-03-02 Mckay William F Controlled and directed local delivery of anti-inflammatory compositions
CN1311818C (zh) * 2004-11-22 2007-04-25 山东蓝金生物工程有限公司 一种抗实体肿瘤的药物组合物
CA2588908C (en) * 2004-11-29 2014-09-23 Yeda Research And Development Co. Ltd Induction of neurogenesis and stem cell therapy in combination with copolymer 1
US8128952B2 (en) * 2005-01-12 2012-03-06 Clemson University Research Foundation Ligand-mediated controlled drug delivery
CN101500606B (zh) * 2005-06-24 2013-12-04 杜克大学 基于热反应生物聚合物的直接药物送递系统
US9012605B2 (en) 2006-01-23 2015-04-21 Amgen Inc. Crystalline polypeptides
US20090183503A1 (en) * 2008-01-18 2009-07-23 Alberto Verdesi Exhaust apparatus
CA2721927C (en) 2008-04-21 2014-01-28 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
US10092580B2 (en) 2008-07-21 2018-10-09 Otonomy, Inc. Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
US8784870B2 (en) * 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
CR20160147A (es) 2011-03-25 2016-08-03 Amgen Inc Formulaciones de anticuerpos
US20150125471A1 (en) * 2012-05-03 2015-05-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment and diagnotic of anemia of inflammation
WO2014046631A1 (en) 2012-09-19 2014-03-27 Tezcaner Aysen CONTROLED DRUG DELIVERY SYSTEMS FOR ANTI-TNF-α
WO2015119653A1 (en) 2014-02-04 2015-08-13 Abbott Cardiovascular Systems Inc. Drug delivery scaffold or stent with a novolimus and lactide based coating such that novolimus has a minimum amount of bonding to the coating
AU2015289874A1 (en) 2014-07-14 2017-02-02 Amgen Inc. Crystalline antibody formulations
US10611850B2 (en) 2014-07-14 2020-04-07 Amgen Inc. Crystalline antibody formulations
US9775978B2 (en) 2014-07-25 2017-10-03 Warsaw Orthopedic, Inc. Drug delivery device and methods having a retaining member
US10080877B2 (en) 2014-07-25 2018-09-25 Warsaw Orthopedic, Inc. Drug delivery device and methods having a drug cartridge
EP3328898B8 (en) 2015-07-28 2024-04-10 6452728 Canada Corp. Trkb or trkc agonist compositions and methods for the treatment of otic conditions
JP5938762B1 (ja) 2015-09-01 2016-06-22 日揮株式会社 マイクロカプセル製剤及びその製造方法
US10076650B2 (en) 2015-11-23 2018-09-18 Warsaw Orthopedic, Inc. Enhanced stylet for drug depot injector
USD802757S1 (en) 2016-06-23 2017-11-14 Warsaw Orthopedic, Inc. Drug pellet cartridge
JP7033789B2 (ja) 2016-06-29 2022-03-11 オトノミー，インク． トリグリセリド耳用製剤とその使用
US10434261B2 (en) 2016-11-08 2019-10-08 Warsaw Orthopedic, Inc. Drug pellet delivery system and method
KR20200108873A (ko) 2018-01-09 2020-09-21 오토노미, 인코포레이티드 성장 인자 귀 제제
SG11202005947RA (en) 2018-05-24 2020-07-29 Celanese Eva Performance Polymers Corp Implantable device for sustained release of a macromolecular drug compound
WO2019226519A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
WO2019222856A1 (en) 2018-05-24 2019-11-28 Nureva Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US5114719A (en) * 1987-04-29 1992-05-19 Sabel Bernhard A Extended drug delivery of small, water-soluble molecules
US4883666A (en) * 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
IL98078A0 (en) * 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
SE8804164A0 (sv) * 1988-11-17 1990-05-18 Per Prisell Farmaceutisk beredning
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5478564A (en) * 1990-02-22 1995-12-26 Teva Pharmaceutical Industries, Ltd. Preparation of microparticles for controlled release of water-soluble substances
US5206023A (en) * 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5330768A (en) * 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
WO1993015722A1 (en) * 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
WO1994006476A1 (en) * 1992-09-15 1994-03-31 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
EP0646000A4 (en) * 1992-11-16 1997-05-02 Univ Mercer COMPOSITIONS CONTAINING MICRO-ENCODED NEUTRALIZING ANTIBODIES.

Also Published As

Publication number Publication date
NO20056197L (no) 1997-11-03
EP0812208A1 (en) 1997-12-17
UA44761C2 (uk) 2002-03-15
AU692384B2 (en) 1998-06-04
CN1133464C (zh) 2004-01-07
EP0812208A4 (en) 2004-06-30
US6083534A (en) 2000-07-04
PT812208E (pt) 2009-02-06
JP4447052B2 (ja) 2010-04-07
NO323003B1 (no) 2006-12-18
DK0812208T3 (da) 2009-03-16
CN1182369A (zh) 1998-05-20
DE69637768D1 (de) 2009-01-15
WO1996026738A1 (en) 1996-09-06
MX9706626A (es) 1998-02-28
KR19980702640A (ko) 1998-08-05
JPH11501306A (ja) 1999-02-02
NO973812L (no) 1997-11-03
ATE415941T1 (de) 2008-12-15
AU5303996A (en) 1996-09-18
ES2318849T3 (es) 2009-05-01
KR100417650B1 (ko) 2004-05-20
NO328034B1 (no) 2009-11-16
EA199700206A1 (ru) 1998-02-26
CA2213560A1 (en) 1996-09-06
IL112834A0 (en) 1995-06-29
NO973812D0 (no) 1997-08-19
BR9607289A (pt) 1998-06-23
CA2213560C (en) 2010-08-24
EP0812208B1 (en) 2008-12-03

Similar Documents

Publication Publication Date Title
IL112834A (en) Pharmaceutical compositions for controlled release of soluble receptors
US4968317B1 (en) Surgical materials and devices
GB2246295B (en) Continuous release pharmaceutical compositions
IS4187A (is) Ný lyfjablanda til inntöku um munn sem inniheldurnýtt magnesíumsalt ómeprasóls, aðferð við framleiðslu hennar og notkun
NZ291417A (en) Use of a progesterone antagonist and of a gestagen for the treatment of endometriosis or leiomyomata uteri
GB9408775D0 (en) Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
TW228474B (no)
GR3030032T3 (en) Human il-3 variants.
IL134268A0 (en) Pharmaceutical compositions containing vitamin d and calcium, their preparation and therapeutic use
SE9501671D0 (sv) Method and composition for prevention of posterior capsule opacification
GEP20032906B (en) Controlled Release Peroral Pharmaceutical Composition of Levosimendan for Treatment of Congestive Heart Failure
AU5766790A (en) Liquid polymer composition, and method of use

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired